NSCLC: primary tumor size--radiation dose-related accelerated, twice daily radiotherapy by target splitting, preceded by 2 cycles of chemotherapy--first results of a prospective study

Strahlenther Onkol. 2007 Dec:183 Spec No 2:38-40. doi: 10.1007/s00066-007-2015-4.
No abstract available

Publication types

  • Comparative Study

MeSH terms

  • Actuarial Analysis
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use
  • Carboplatin / administration & dosage
  • Carboplatin / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / mortality
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Carcinoma, Non-Small-Cell Lung / radiotherapy*
  • Cisplatin / administration & dosage
  • Cisplatin / therapeutic use
  • Combined Modality Therapy
  • Female
  • Follow-Up Studies
  • Humans
  • Lung / pathology
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / mortality
  • Lung Neoplasms / pathology
  • Lung Neoplasms / radiotherapy*
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Prospective Studies
  • Radiation-Sensitizing Agents / administration & dosage
  • Radiation-Sensitizing Agents / therapeutic use
  • Radiotherapy Dosage
  • Radiotherapy, Conformal*
  • Randomized Controlled Trials as Topic
  • Time Factors

Substances

  • Antineoplastic Agents
  • Radiation-Sensitizing Agents
  • Carboplatin
  • Cisplatin